Go offline with the Player FM app!
The ACORN Study: Nephrotoxoicity in Antibiotics
Manage episode 383558719 series 2931422
Piperacillin/tazobactam and vancomycin have been reported in numerous clinical trials to be associated with acute kidney injury. Comparatively, cefepime with vancomycin may increase neurotoxic effects. Join host, Geoff Wall, as he evaluates a new randomized controlled trial evaluating the safety of these medications.
The GameChanger
Vancomycin, even at appropriate doses, can cause nephrotoxicity. Piperacillin/tazobactam does not seem to increase the risk of adverse kidney outcomes. However, cefepime is associated with an increased risk of neurologic toxicity.
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
Tong SYC, Venkatesh B, McCreary EK. Acute Kidney Injury With Empirical Antibiotics for Sepsis. JAMA. 2023;330(16):1531–1533. doi:10.1001/jama.2023.18591
https://jamanetwork.com/journals/jama/fullarticle/2810593
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the risk of nephrotoxicity with piperacillin/tazobactam
2. Discuss the factors that exacerbate neurologic adverse effects with cefepime
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-353-H01-P
Initial release date: 11/13/2023
Expiration date: 11/13/2024
Additional CPE details can be found here.
Chapters
1. The ACORN Study: Nephrotoxoicity in Antibiotics (00:00:00)
2. The Acorn Study (00:00:08)
3. Comparing Cephipene and PIP-Tazo in Kidney Study (00:11:30)
4. Comparing Antibiotics in Patient Outcomes (00:18:41)
298 episodes
Manage episode 383558719 series 2931422
Piperacillin/tazobactam and vancomycin have been reported in numerous clinical trials to be associated with acute kidney injury. Comparatively, cefepime with vancomycin may increase neurotoxic effects. Join host, Geoff Wall, as he evaluates a new randomized controlled trial evaluating the safety of these medications.
The GameChanger
Vancomycin, even at appropriate doses, can cause nephrotoxicity. Piperacillin/tazobactam does not seem to increase the risk of adverse kidney outcomes. However, cefepime is associated with an increased risk of neurologic toxicity.
Host
Geoff Wall, PharmD, BCPS, FCCP, BCGP
Professor of Pharmacy Practice, Drake University
Internal Medicine/Critical Care, UnityPoint Health
Reference
Tong SYC, Venkatesh B, McCreary EK. Acute Kidney Injury With Empirical Antibiotics for Sepsis. JAMA. 2023;330(16):1531–1533. doi:10.1001/jama.2023.18591
https://jamanetwork.com/journals/jama/fullarticle/2810593
Pharmacist Members, REDEEM YOUR CPE HERE!
Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)
CPE Information
Learning Objectives
Upon successful completion of this knowledge-based activity, participants should be able to:
1. Describe the risk of nephrotoxicity with piperacillin/tazobactam
2. Discuss the factors that exacerbate neurologic adverse effects with cefepime
0.05 CEU/0.5 Hr
UAN: 0107-0000-23-353-H01-P
Initial release date: 11/13/2023
Expiration date: 11/13/2024
Additional CPE details can be found here.
Chapters
1. The ACORN Study: Nephrotoxoicity in Antibiotics (00:00:00)
2. The Acorn Study (00:00:08)
3. Comparing Cephipene and PIP-Tazo in Kidney Study (00:11:30)
4. Comparing Antibiotics in Patient Outcomes (00:18:41)
298 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.